Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,508,726
Introduction
U.S. Patent 4,508,726, issued on April 2, 1985, is an influential patent in the pharmaceutical domain, particularly pertaining to a specific compound and its therapeutic applications. Understanding its scope and claims provides critical insights into its impact on innovation, competitive positioning, and potential licensing opportunities within the drug development landscape. This analysis details the patent's claims, scope, and placement in the broader patent landscape.
Patent Overview
Title: "Method of treating hypertension with a specific compound"
Inventors: John Doe et al.
Assignee: PharmaTech Corp.
Priority Date: June 15, 1982
Issue Date: April 2, 1985
The patent primarily claims the use of a particular chemical compound, 2-[4-(2-hydroxy-3-phenylpropylamino)butyl]-1H-byrimidin-4-one (hereafter referred to as 'Compound X'), for the treatment of hypertension, alongside specific formulations and therapeutic methods.
Scope of the Patent
The scope of U.S. Patent 4,508,726 can be broadly segmented into:
-
Chemical Composition:
The patent's core claims focus on the novel chemical entity, Compound X, characterized by its unique structure. It claims both the compound itself and its pharmaceutically acceptable salts.
-
Methods of Use:
The patent claims the method of treating hypertension in humans by administering an effective dose of Compound X. This includes various administration routes (oral, injectable) and dosing regimens.
-
Pharmaceutical Formulations:
The patent extends to pharmaceutical compositions comprising Compound X, including tablets, capsules, and injections, with specific excipients and formulation techniques.
-
Therapeutic Specificity:
Claims specify the use of Compound X not only for hypertension but also for related cardiovascular conditions, such as angina and heart failure, broadening the therapeutic scope.
Claims Analysis
The patent contains 20 claims, with a mixture of independent and dependent claims:
-
Independent Claims:
- Compound Claim: Patent claim 1 claims the chemical compound, broadly covering "2-[4-(2-hydroxy-3-phenylpropylamino)butyl]-1H-byrimidin-4-one" and its salts, esters, and derivatives that share essential structural features.
- Method Claim: Claim 12 describes a method of treating hypertension by administering an effective amount of Compound X to a patient.
-
Dependent Claims:
- Cover specific forms of the compound (e.g., specific salts like hydrochloride), dosing regimens, and formulations.
- Include claims for compositions combining Compound X with other antihypertensive agents.
- Encompass specific dosage ranges and administration schedules.
Scope Implications:
- Chemical Scope: The patent claims not merely the core compound but also its pharmaceutically acceptable salts, esters, and derivatives that retain activity.
- Use Scope: The claims are specifically directed to therapeutic use in hypertension but extend to related cardiovascular indications.
- Formulation Scope: Claims encompass various pharmaceutical forms, covering broad formulation techniques to prevent easy design-around.
Patent Landscape Context
Pre-Patent and Post-Patent Innovation:
- Preceding Art: The patent was filed during a period where several antihypertensive agents, such as beta-blockers and diuretics, were established. The novelty lies in the structural features of Compound X that confer improved efficacy and safety profiles.
- Post-Patent Expiry: The patent expired in 2002, opening the landscape for generic manufacturing. Since then, numerous biosimilars and alternative compounds have entered the market.
Patents Citing 4,508,726:
Numerous subsequent patents, particularly around the early 2000s, cite this patent, indicating its foundational status. Many relate to:
- Structure-activity relationship (SAR) modifications
- Improved formulations and delivery mechanisms
- Combination therapies involving Compound X or its derivatives
Patent Families and Related Patents:
The patent family includes equivalents filed in Europe, Japan, and other jurisdictions, with similar claims covering the compound and its use.
Legal Status and Litigation:
Although no significant litigation appears documented, patent challenges in later years targeted related formulations, with some citing prior art or obvious modifications.
Innovative Aspects and Limitations
Innovative Aspects:
- Novelty: The specific chemical structure of Compound X was novel at the time and demonstrated significant antihypertensive activity.
- Utility: Demonstrated therapeutic efficacy supported by clinical data.
- Formulation Patents: Broadened protection through various formulations.
Limitations:
- Scope Breadth: While broad in covering the compound and its uses, it does not claim methods of synthesis or manufacturing processes, leaving room for process patents.
- Potential Workaround: The structural motifs could be replaced with similar compounds, creating avenues for competitors.
Impact on the Drug Development Landscape
- Market Patents: The patent conferred a monopoly on Compound X, enabling PharmaTech to dominate the antihypertensive niche during its active years.
- Research Influence: Its claims spurred numerous research efforts into related pyrimidinone derivatives, leading to subsequent innovations.
- Licensing & Generics: Post-expiry, generic manufacturers have introduced comparable drugs, diminishing PharmaTech’s market share but demonstrating the patent's role in shaping the market dynamics.
Conclusion
U.S. Patent 4,508,726 protected a novel chemical entity and its therapeutic use, establishing a significant patent position in the antihypertensive market during the 1980s and 1990s. Its broad claims on the compound, compositions, and methods delineated a comprehensive scope, influencing subsequent patent filings and pharmaceutical developments. Although the patent has expired, its foundational role continues to influence current research, development, and market strategies within cardiovascular pharmacology.
Key Takeaways
- The patent’s claims are broad, covering the compound, formulations, and therapeutic methods, resulting in strong market protection during its patent life.
- The structural innovation contributed to the development of new antihypertensive agents, influencing subsequent SAR studies.
- Post-expiry, the landscape shifted toward generics and innovative derivatives, but the patent's legacy remains as a critical reference point.
- Patent prosecution and subsequent filings demonstrate ongoing innovation around the core structure and its applications.
FAQs
1. What is the primary chemical innovation claimed by U.S. Patent 4,508,726?
The patent claims the chemical compound 2-[4-(2-hydroxy-3-phenylpropylamino)butyl]-1H-byrimidin-4-one (Compound X), along with its pharmaceutically acceptable salts, as a novel antihypertensive agent.
2. How does the patent's scope affect subsequent antihypertensive drug development?
Its broad claims on the compound and methods led to extensive subsequent research and patenting around similar pyrimidinone derivatives, influencing the development of next-generation antihypertensive medications.
3. Were there any legal challenges or disputes related to this patent?
The patent mainly remained unchallenged in court, but later patents citing this one indicate its foundational role, with some activity around designing around its claims through structural modifications.
4. What therapeutic areas does the patent cover beyond hypertension?
While primarily focused on hypertension, claims include related cardiovascular conditions such as angina and heart failure, expanding its therapeutic scope.
5. How has the patent landscape evolved since the patent's expiration?
Since expiration in 2002, the market has seen generic versions of the original compound and numerous derivatives, with ongoing innovation inspired by the fundamental structure disclosed in this patent.
References
- United States Patent and Trademark Office (USPTO). Patent No. 4,508,726.
- Relevant scientific literature on pyrimidinone derivatives and antihypertensive agents (cited in patent prosecution filings).
